A continent of 1.5 billion people, 55 nations, and a pharmaceutical market projected to top $50 billion by 2030 currently lacks a unified system for approving and regulating medical products. That gap, long recognized as a structural vulnerability in global health security, is what the African Medicines Agency (AMA) was created to close — and its Director General is making the case that the stakes extend well beyond Africa’s borders.
Writing in The Telegraph on May 5, Dr. Delese Mimi Darko, Director General of the AMA, outlined the agency’s mandate and the urgency behind it. Established by African Union member states, the AMA is designed to harmonize pharmaceutical regulation across the continent — modeled in part on the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), but built around Africa’s distinct needs and realities.
At present, each of Africa’s 55 countries maintains its own regulatory framework, standards, and approval processes. The result is a patchwork system that imposes significant logistical and financial burdens on both local and international manufacturers seeking to bring products to market continent-wide. When regulatory barriers are high and complex, investment in local manufacturing stalls, competition thins, and supply chains become brittle — precisely the conditions that amplify risk during pandemics and other health emergencies.
Regulatory gaps also create fertile ground for substandard and falsified medicines. Dr. Darko points to a stark example: the deaths of at least 66 children in the Gambia in 2022, linked to contaminated cough syrups manufactured in India. Without robust, coordinated quality assurance and safety monitoring systems, such tragedies remain a persistent threat.
Thirty-one countries have ratified the treaty so far — a meaningful foundation, but short of what the agency considers necessary to achieve continental scale. Efforts are ongoing for African Union member states to ratify the treaty and to back the agency financially through predictable, nationally budgeted contributions.
The world’s health system is only as strong as its weakest part. A continent without coordinated pharmaceutical regulation is a continent more vulnerable to supply shocks, counterfeit medicines, and slow pandemic response — and those vulnerabilities ripple outward.
Sources and further reading:
How the African Medicines Agency will transform global health security – The Telegraph